Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862699 | 0.90 | F2 (0.52) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL24131608 | 0.85 | F2 (0.59) | F2PRSS1 | |
| SCHEMBL24131464 | 0.85 | F2 (0.59) | F2PRSS1 | |
| SCHEMBL24131389 | 0.85 | F2 (0.59) | F2PRSS1 | |
| SCHEMBL24115250 | 0.85 | F2 (0.59) | F2PRSS1 | |
| SCHEMBL5860097 | 0.85 | F2 (0.58) | F2PRSS1 | |
| SCHEMBL24115255 | 0.85 | F2 (0.56) | F2PRSS1 | |
| SCHEMBL5860154 | 0.84 | F2 (0.60) | F2PRSS1 | |
| SCHEMBL5862705 | 0.84 | F2 (0.58) | F2PRSS1 | |
| SCHEMBL7536130 | 0.84 | F2 (0.58) | F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | claimed |
| US-6469036-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH THE RESPIRATORY TRACT, SUCH AS ASTHMA AND ALLERGIC RHINITIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-22 | — | — | US | claimed |
| US-7132418-B2 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | disclosed |
| US-6469036-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH THE RESPIRATORY TRACT, SUCH AS ASTHMA AND ALLERGIC RHINITIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | CMA1, TPSB2, TPSAB1 | F2 410/4885PRSS1 9/4885PRSS2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.